Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Committee
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio-Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Application Process
    • The CARB-X Process
    • Official Development Assistance
    • Research Compliance
    • Additional Information and Resources
    • Apply Here
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
    • Media Resources
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Committee
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio-Product Developers
    • CARB-X Graduates
    • Spotlight on Science
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Application Process
    • The CARB-X Process
    • Official Development Assistance
    • Research Compliance
    • Additional Information and Resources
    • Apply Here
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
    • Media Resources
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Entasis NPLP

ENTASIS THERAPEUTICS, INC. Waltham, MA, USA
entasistx.com

NON-BL PBPI
NON-BETA-LACTAM PBPI

Direct-Acting Small Molecule Therapeutic
Entasis Therapeutics is developing a novel antibiotic class targeting the penicillin-binding proteins (PBPs), cell wall targets unique to bacteria. While beta-lactams kill bacteria by binding to PBPs, bacteria have evolved to produce beta-lactamases which inactivate these agents. Entasis’ non-beta-lactam PBP inhibitors are unaffected by all four classes of beta-lactamases while demonstrating remarkable antibacterial activity. The lead compound demonstrates potent in vitro and in vivo antibacterial activity against some of the toughest to treat Gram-negative pathogens, including multi-drug-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacteriaceae, and multi-drug-resistant Acinetobacter baumannii.

Current Development Stage: Pre-Clinical

CARB-X Investment: Initial investment of up to $3.8m with potential option payments up to $6.3m.  Additional investment of up to $5.63m to complete IND-enabling studies.

Initial CARB-X Investment Date: October 1, 2017

Read their Spotlight on Science

Carb-X

Led by Boston University

Copyright 2022

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2022